All TACE procedures were performed by 1 of 3 interventional physicians. A 5F catheter (Terumo, Tokyo, Japan) or a 2.7F microcatheter (Renegade Hi-Flo Straight, Boston scientific, Natick, Mass; Progreat, Terumo, Tokyo, Japan) was employed for tumor-feeding artery superselective therapy. An emulsion of 5–20 ml Lipiodol (Lipiodol; Guerbet, Aulnay-Sous-Bois, France) and 20–60 mg epirubicin (Pharmorubicin; Pfizer, New York, USA) were administered into the tumor-feeding vessels. The specific dose of Lipiodol was determined based on the tumor number and volume. Then, 350–560 mm absorbable gelatin sponge particles (Gelfoam; Hangzhou Pharmaceutical, Linan, China) were administered into the tumor-feeding vessels. The embolization finishes when the radiocontrast agent stopped flowing for 5 cardiac cycles.
Renegade hi flo straight
Manufactured by Boston Scientific
Sourced in Japan
The Renegade Hi-Flo Straight is a laboratory equipment product designed for fluid handling applications. It features a straight configuration for controlled and precise fluid delivery. The core function of this product is to facilitate the movement and transfer of various liquids and solutions within a laboratory setting.
Automatically generated - may contain errors
Lab products found in correlation
4 protocols using renegade hi flo straight
1
TACE Procedure for Tumor Embolization
2
Transarterial Chemoembolization for Liver Cancer
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
TACE was performed by one of four physicians. TACE was performed by placing a 5-F catheter (Cook, Bloomington, Indiana) or a 2.8-F microcatheter (Renegade Hi-Flo Straight, Boston Scientific, Natick, Mass; Progreat, Terumo, Tokyo, Japan) as superselectively as possible into tumor-feeding arteries. Initially, a lobaplatin solution with a concentration of 0.5 mg/mL was infused into the tumor-feeding vessels. The total lobaplatin level was 20-50 mg and depended on the patient’s body weight. Then, an emulsion of 3–10 mL lipiodol (Lipiodol Ultrafluide; Guerbet, Aulnay-Sous-Bois, France) and 20–60 mg doxorubicin hydrochloride was administered into the feeder vessels. Finally, polyvinyl alcohol particles 300 μm in diameter (Polyvinyl Alcohol Foam Embolization Particles; Cook) mixed with contrast material were administered into the tumor-feeding vessels until arterial flow stasis was achieved. After embolization, angiography of the feeding artery was performed to determine the extent of vascular occlusion. If the feeding artery was not completely occluded, polyvinyl alcohol particle embolism was performed again.
3
Transarterial Chemoembolization Protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
TACE procedures were performed by two of three experienced interventional radiologists (W.F., Y.W., and J.L.). Hepatic angiography was performed by placing a 5-F catheter (Terumo, Tokyo, Japan) or a 2.7-F microcatheter (Renegade Hi-Flo Straight, Boston Scientific, Natick, MA; Progreat, Terumo) as superselectively as possible into tumor-feeding arteries. An emulsion of 5-20 mL Lipiodol (Lipiodol, Guerbet, Aulnay-Sous-Bois, France) or drug-loaded microspheres (DC-Bead [DCB], SciClone, Shanghai, China) and 20-80 mg of epirubicin (Pharmorubicin, Pfizer, New York, NY) were administered into feeder vessels. Then, 350-560-mm absorbable gelatin sponge particles (Gelfoam, Hangzhou Pharmaceutical, Hangzhou, China) were administered into tumor-feeding vessels. Particle size of DCB microspheres were selected according to angiogr-aphic blood flow velocity. After embolization, angiography of the feeding artery was performed to determine the extent of vascular occlusion. If reflux occurred, the use of Lipiodol, DCB microspheres, or absorbable gelatin sponge particles will be discontinued.
4
TACE for Liver Tumor Treatment
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
TACE was performed under the guidance of digital subtraction angiography (DSA) by interventional radiologists with more than 10 years of experience in endovascular interventional therapy. If TACE was performed ≤1 week prior to systemic therapies, TACE could also be counted as concurrent therapy. The chemotherapeutic agents, embolization materials used in TACE, and detailed TACE procedures were as described in previously published articles (18 (link)). In short, a 2.8-F microcatheter (Renegade HiFlo Straight, Boston Scientific, Natick, MA, USA; Progreat, Terumo, Tokyo, Japan) was advanced as selectively as possible into the tumor feeding arteries. The lobaplatin concentration was 0.5 mg/mL and the total dose was 0.5 mg/kg. Lobaplatin was mixed with lipiodol at a ratio of 1:2 or 1:3. After administration of the chemotherapeutic/lipiodol mixture, 300 µm polyvinyl alcohol particles (PVA; Cook, Bloomington, IN, USA) were injected into the tumor-feeding arteries. Post embolization, occlusion of tumor supply was confirmed by angiography. Repeat TACE was allowed if the 1 month follow-up imaging demonstrated residual tumor and liver function was maintained.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!